Detailed explanation of the mechanism of action and clinical application of entrectinib

Enrectinib, as an innovative broad-spectrum anti-cancer drug developed by Roche Genentech, has been approved for marketing in many countries and regions around the world, including Japan, the United States, and the European Union, and will successfully enter the Chinese market in 2022. This targeted therapy drug, with its unique advantages, brings new treatment options and hope to patients with specific types of cancer.

The main mechanism of action of entrectinib is that it can precisely inhibit the activity of specific tyrosine kinases, thereby effectively interfering with the growth and spread of cancer cells. This precise targeting effect enables entrectinib to exhibit excellent results in cancer treatment. Especially for patients with ROS1-positive metastatic non-small cell lung cancer, entrectinib has become an important treatment option, which can significantly extend the patient's survival and improve their quality of life.

In addition to its use in non-small cell lung cancer, entrectinib is particularly indicated for the treatment of patients with solid tumors harboring neurotrophic tyrosine receptor kinase(NTRK) gene fusions without known acquired resistance mutations. These patients often face the risk of significant morbidity from surgical resection, or have their condition worsen after treatment and lack satisfactory alternative therapies. For these patients, entrectinib provides a new treatment option that can effectively inhibit the growth of cancer cells, help patients control their disease, reduce symptoms, and improve their quality of life.

To sum up, entrectinib, as a new broad-spectrum anticancer drug, has been widely recognized for its role and main functions in cancer treatment. Especially in the treatment of ROS1positive metastatic non-small cell lung cancer and solid tumors with specific gene fusions, entrectinib has demonstrated significant therapeutic effects and good safety. However, patients still need to follow their doctor's instructions when using entrectinib, pay close attention to their body's reaction, and communicate any discomfort or abnormal symptoms with their doctor in a timely manner to ensure the safety and effectiveness of the treatment. Currently, there are many versions of entrectinib available. Patients are advised to consult a professional doctor and make the appropriate choice according to their own needs.